PRRT2 and familial Mediterranean fever: Colchicine treatment is unlikely to explain the hyper‐reactivity of FMF patients to PKC superfamily inhibitors since (i) we could recapitulate the findings in U937 cells; (ii) in vitro, colchicine reduces inflammasome activation (Gao et al, 2016; Park et al, 2016; Van Gorp et al, 2016); and (iii) three patients with Behcet's disease under colchicine were included in the disease control group and their monocytes did not display an FMF‐like phenotype.